Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 555

1.

Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial.

Seferovic JP, Pfeffer MA, Claggett B, Desai AS, de Zeeuw D, Haffner SM, McMurray JJV, Parving HH, Solomon SD, Chaturvedi N.

Diabetologia. 2018 Mar;61(3):581-588. doi: 10.1007/s00125-017-4485-y. Epub 2017 Nov 3.

PMID:
29098323
2.

Individual serum saturated fatty acids and markers of chronic subclinical inflammation: the Insulin Resistance Atherosclerosis Study.

Santaren ID, Watkins SM, Liese AD, Wagenknecht LE, Rewers MJ, Haffner SM, Lorenzo C, Festa A, Bazinet RP, Hanley AJ.

J Lipid Res. 2017 Nov;58(11):2171-2179. doi: 10.1194/jlr.P076836. Epub 2017 Sep 19.

3.

Association of Directly Measured Plasma Free 25(OH)D With Insulin Sensitivity and Secretion: The IRAS Family Study.

Lee CC, Young KA, Norris JM, Rotter JI, Liu Y, Lorenzo C, Wagenknecht LE, Cole DE, Haffner SM, Chen YI, Hanley AJ.

J Clin Endocrinol Metab. 2017 Aug 1;102(8):2781-2788. doi: 10.1210/jc.2017-00039.

4.

Updated risk factors should be used to predict development of diabetes.

Bethel MA, Hyland KA, Chacra AR, Deedwania P, Fulcher GR, Holman RR, Jenssen T, Levitt NS, McMurray JJV, Boutati E, Thomas L, Sun JL, Haffner SM; NAVIGATOR Study Group.

J Diabetes Complications. 2017 May;31(5):859-863. doi: 10.1016/j.jdiacomp.2017.02.012. Epub 2017 Mar 2.

PMID:
28319004
5.

Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.

Currie G, Bethel MA, Holzhauer B, Haffner SM, Holman RR, McMurray JJV.

Diabetes Obes Metab. 2017 Jun;19(6):791-799. doi: 10.1111/dom.12877. Epub 2017 Mar 17.

PMID:
28093841
6.

Novel Protein Glycan-Derived Markers of Systemic Inflammation and C-Reactive Protein in Relation to Glycemia, Insulin Resistance, and Insulin Secretion.

Lorenzo C, Festa A, Hanley AJ, Rewers MJ, Escalante A, Haffner SM.

Diabetes Care. 2017 Mar;40(3):375-382. doi: 10.2337/dc16-1569. Epub 2016 Dec 28.

7.

Branched-Chain Amino Acids and Insulin Metabolism: The Insulin Resistance Atherosclerosis Study (IRAS).

Lee CC, Watkins SM, Lorenzo C, Wagenknecht LE, Il'yasova D, Chen YD, Haffner SM, Hanley AJ.

Diabetes Care. 2016 Apr;39(4):582-8. doi: 10.2337/dc15-2284. Epub 2016 Feb 19.

8.

Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial.

Heerspink HJ, Ninomiya T, Persson F, Brenner BM, Brunel P, Chaturvedi N, Desai AS, Haffner SM, Mcmurray JJ, Solomon SD, Pfeffer MA, Parving HH, de Zeeuw D.

Diabetes Obes Metab. 2016 Feb;18(2):169-77. doi: 10.1111/dom.12600. Epub 2016 Jan 13.

PMID:
26511599
9.

Lipoprotein heterogeneity may help to detect individuals with insulin resistance.

Lorenzo C, Hanley AJ, Rewers MJ, Festa A, Haffner SM.

Diabetologia. 2015 Dec;58(12):2765-73. doi: 10.1007/s00125-015-3743-0. Epub 2015 Sep 4.

PMID:
26341113
10.

Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study.

Preiss D, Thomas LE, Wojdyla DM, Haffner SM, Gill JM, Yates T, Davies MJ, Holman RR, McMurray JJ, Califf RM, Kraus WE; NAVIGATOR Investigators.

BMJ Open. 2015 Aug 14;5(8):e007901. doi: 10.1136/bmjopen-2015-007901.

11.

Associations of coffee consumption with markers of liver injury in the insulin resistance atherosclerosis study.

Dickson JC, Liese AD, Lorenzo C, Haffner SM, Watkins SM, Hamren SJ, Stiles JK, Wagenknecht LE, Hanley AJ.

BMC Gastroenterol. 2015 Jul 28;15:88. doi: 10.1186/s12876-015-0321-3.

12.

Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial.

Jhund PS, McMurray JJ, Chaturvedi N, Brunel P, Desai AS, Finn PV, Haffner SM, Solomon SD, Weinrauch LA, Claggett BL, Pfeffer MA.

Eur Heart J. 2015 Sep 21;36(36):2463-9. doi: 10.1093/eurheartj/ehv295. Epub 2015 Jul 18.

PMID:
26188211
13.

Discriminatory value of alanine aminotransferase for diabetes prediction: the Insulin Resistance Atherosclerosis Study.

Lorenzo C, Hanley AJ, Rewers MJ, Haffner SM.

Diabet Med. 2016 Mar;33(3):348-55. doi: 10.1111/dme.12835. Epub 2015 Jul 16.

14.

Reply: To PMID 25499404.

Després JP, Nazare JA, Balkau B, Haffner SM, Brulle-Wohlhueter C.

Am J Cardiol. 2015 Jul 15;116(2):336-7. doi: 10.1016/j.amjcard.2015.04.033. Epub 2015 Apr 23. No abstract available.

PMID:
25983124
15.

Improving Adiponectin Levels in Individuals With Diabetes and Obesity: Insights From Look AHEAD.

Belalcazar LM, Lang W, Haffner SM, Schwenke DC, Kriska A, Balasubramanyam A, Hoogeveen RC, Pi-Sunyer FX, Tracy RP, Ballantyne CM; Look AHEAD (Action for Health in Diabetes) Research Group.

Diabetes Care. 2015 Aug;38(8):1544-50. doi: 10.2337/dc14-2775. Epub 2015 May 13.

16.

Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial.

Yates T, Davies MJ, Haffner SM, Schulte PJ, Thomas L, Huffman KM, Bales CW, Preiss D, Califf RM, Holman RR, McMurray JJ, Bethel MA, Tuomilehto J, Kraus WE.

Diabet Med. 2015 Aug;32(8):1090-6. doi: 10.1111/dme.12762. Epub 2015 Apr 12.

PMID:
25818859
17.

Glycated hemoglobin levels are mostly dependent on nonglycemic parameters in 9398 Finnish men without diabetes.

Fizelova M, Stančáková A, Lorenzo C, Haffner SM, Cederberg H, Kuusisto J, Laakso M.

J Clin Endocrinol Metab. 2015 May;100(5):1989-96. doi: 10.1210/jc.2014-4121. Epub 2015 Mar 3.

PMID:
25734252
18.

Usefulness of measuring both body mass index and waist circumference for the estimation of visceral adiposity and related cardiometabolic risk profile (from the INSPIRE ME IAA study).

Nazare JA, Smith J, Borel AL, Aschner P, Barter P, Van Gaal L, Tan CE, Wittchen HU, Matsuzawa Y, Kadowaki T, Ross R, Brulle-Wohlhueter C, Alméras N, Haffner SM, Balkau B, Després JP; INSPIRE ME IAA Investigators.

Am J Cardiol. 2015 Feb 1;115(3):307-15. doi: 10.1016/j.amjcard.2014.10.039. Epub 2014 Nov 13. Erratum in: Am J Cardiol. 2015 May 1;115(9):1323.

PMID:
25499404
19.

Serum pentadecanoic acid (15:0), a short-term marker of dairy food intake, is inversely associated with incident type 2 diabetes and its underlying disorders.

Santaren ID, Watkins SM, Liese AD, Wagenknecht LE, Rewers MJ, Haffner SM, Lorenzo C, Hanley AJ.

Am J Clin Nutr. 2014 Dec;100(6):1532-40. doi: 10.3945/ajcn.114.092544. Epub 2014 Oct 8.

20.

Fasting and OGTT-derived measures of insulin resistance as compared with the euglycemic-hyperinsulinemic clamp in nondiabetic Finnish offspring of type 2 diabetic individuals.

Lorenzo C, Haffner SM, Stančáková A, Kuusisto J, Laakso M.

J Clin Endocrinol Metab. 2015 Feb;100(2):544-50. doi: 10.1210/jc.2014-2299. Epub 2014 Nov 11.

PMID:
25387258
21.

Visceral, subcutaneous abdominal adiposity and liver fat content distribution in normal glucose tolerance, impaired fasting glucose and/or impaired glucose tolerance.

Borel AL, Nazare JA, Smith J, Aschner P, Barter P, Van Gaal L, Eng Tan C, Wittchen HU, Matsuzawa Y, Kadowaki T, Ross R, Brulle-Wohlhueter C, Alméras N, Haffner SM, Balkau B, Després JP.

Int J Obes (Lond). 2015 Mar;39(3):495-501. doi: 10.1038/ijo.2014.163. Epub 2014 Sep 2.

PMID:
25179244
22.

Fiber intake and plasminogen activator inhibitor-1 in type 2 diabetes: Look AHEAD (Action for Health in Diabetes) trial findings at baseline and year 1.

Belalcazar LM, Anderson AM, Lang W, Schwenke DC, Haffner SM, Yatsuya H, Rushing J, Vitolins MZ, Reeves R, Pi-Sunyer FX, Tracy RP, Ballantyne CM; Look AHEAD (Action for Health in Diabetes) Research Group.

J Acad Nutr Diet. 2014 Nov;114(11):1800-10.e2. doi: 10.1016/j.jand.2014.06.357. Epub 2014 Aug 15.

23.

Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study.

Preiss D, Haffner SM, Thomas LE, Sun JL, Sattar N, Yates T, J Davies M, McMurray JJ, Holman RR, Califf RM, Kraus WE.

Diabetes Obes Metab. 2014 Dec;16(12):1265-8. doi: 10.1111/dom.12320. Epub 2014 Jun 19.

PMID:
24861892
24.

Calcium and phosphate concentrations and future development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study.

Lorenzo C, Hanley AJ, Rewers MJ, Haffner SM.

Diabetologia. 2014 Jul;57(7):1366-74. doi: 10.1007/s00125-014-3241-9. Epub 2014 Apr 26.

25.

Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR.

Huffman KM, Sun JL, Thomas L, Bales CW, Califf RM, Yates T, Davies MJ, Holman RR, McMurray JJ, Bethel MA, Tuomilehto J, Haffner SM, Kraus WE.

Metabolism. 2014 Apr;63(4):554-61. doi: 10.1016/j.metabol.2014.01.002. Epub 2014 Jan 15.

26.

Disproportionately elevated proinsulinemia is observed at modestly elevated glucose levels within the normoglycemic range.

Lorenzo C, Hanley AJ, Rewers MJ, Haffner SM.

Acta Diabetol. 2014 Aug;51(4):617-23. doi: 10.1007/s00592-014-0565-3. Epub 2014 Feb 15.

PMID:
24532116
27.

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis.

Yates T, Haffner SM, Schulte PJ, Thomas L, Huffman KM, Bales CW, Califf RM, Holman RR, McMurray JJ, Bethel MA, Tuomilehto J, Davies MJ, Kraus WE.

Lancet. 2014 Mar 22;383(9922):1059-66. doi: 10.1016/S0140-6736(13)62061-9. Epub 2013 Dec 20.

PMID:
24361242
28.

Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.

Shen L, Shah BR, Reyes EM, Thomas L, Wojdyla D, Diem P, Leiter LA, Charbonnel B, Mareev V, Horton ES, Haffner SM, Soska V, Holman R, Bethel MA, Schaper F, Sun JL, McMurray JJ, Califf RM, Krum H.

BMJ. 2013 Dec 9;347:f6745. doi: 10.1136/bmj.f6745. Erratum in: BMJ. 2014;348:f1339.

29.

Risk of developing diabetes and cardiovascular disease in metabolically unhealthy normal-weight and metabolically healthy obese individuals.

Aung K, Lorenzo C, Hinojosa MA, Haffner SM.

J Clin Endocrinol Metab. 2014 Feb;99(2):462-8. doi: 10.1210/jc.2013-2832. Epub 2013 Nov 20.

30.

Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.

Latini R, Staszewsky L, Sun JL, Bethel MA, Disertori M, Haffner SM, Holman RR, Chang F, Giles TD, Maggioni AP, Rutten GE, Standl E, Thomas L, Tognoni G, Califf RM, McMurray JJ.

Am Heart J. 2013 Nov;166(5):935-40.e1. doi: 10.1016/j.ahj.2013.08.012. Epub 2013 Oct 7.

PMID:
24176451
31.

Differential white cell count and incident type 2 diabetes: the Insulin Resistance Atherosclerosis Study.

Lorenzo C, Hanley AJ, Haffner SM.

Diabetologia. 2014 Jan;57(1):83-92. doi: 10.1007/s00125-013-3080-0. Epub 2013 Oct 19.

32.

Insulin sensitivity and insulin clearance are heritable and have strong genetic correlation in Mexican Americans.

Goodarzi MO, Langefeld CD, Xiang AH, Chen YD, Guo X, Hanley AJ, Raffel LJ, Kandeel F, Nadler JL, Buchanan TA, Norris JM, Fingerlin TE, Lorenzo C, Rewers MJ, Haffner SM, Bowden DW, Rich SS, Bergman RN, Rotter JI, Watanabe RM, Wagenknecht LE.

Obesity (Silver Spring). 2014 Apr;22(4):1157-64. doi: 10.1002/oby.20639.

33.

Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.

Preiss D, Giles TD, Thomas LE, Sun JL, Haffner SM, Holman RR, Standl E, Mazzone T, Rutten GE, Tognoni G, Chiang FT, McMurray JJ, Califf RM.

Stroke. 2013 Sep;44(9):2590-3. doi: 10.1161/STROKEAHA.113.001177. Epub 2013 Jul 30.

PMID:
23899915
34.

Longitudinal decline of β-cell function: comparison of a direct method vs a fasting surrogate measure: the Insulin Resistance Atherosclerosis Study.

Festa A, Haffner SM, Wagenknecht LE, Lorenzo C, Hanley AJ.

J Clin Endocrinol Metab. 2013 Oct;98(10):4152-9. doi: 10.1210/jc.2013-1937. Epub 2013 Jul 24.

35.

Egg consumption and insulin metabolism in the Insulin Resistance Atherosclerosis Study (IRAS).

Lee CT, Liese AD, Lorenzo C, Wagenknecht LE, Haffner SM, Rewers MJ, Hanley AJ.

Public Health Nutr. 2014 Jul;17(7):1595-602. doi: 10.1017/S1368980013001572. Epub 2013 Jun 19.

PMID:
23777633
36.

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk.

Bethel MA, Chacra AR, Deedwania P, Fulcher GR, Holman RR, Jenssen T, Kahn SE, Levitt NS, McMurray JJ, Califf RM, Raptis SA, Thomas L, Sun JL, Haffner SM.

Am J Cardiol. 2013 Jul 15;112(2):231-7. doi: 10.1016/j.amjcard.2013.03.019. Epub 2013 Apr 19.

PMID:
23608615
37.

Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: from the look AHEAD study.

Belalcazar LM, Haffner SM, Lang W, Hoogeveen RC, Rushing J, Schwenke DC, Tracy RP, Pi-Sunyer FX, Kriska AM, Ballantyne CM; Look AHEAD (Action for Health in Diabetes) Research Group.

Obesity (Silver Spring). 2013 May;21(5):944-50. doi: 10.1002/oby.20431.

38.

Impaired fasting glucose and impaired glucose tolerance have distinct lipoprotein and apolipoprotein changes: the insulin resistance atherosclerosis study.

Lorenzo C, Hartnett S, Hanley AJ, Rewers MJ, Wagenknecht LE, Karter AJ, Haffner SM.

J Clin Endocrinol Metab. 2013 Apr;98(4):1622-30. doi: 10.1210/jc.2012-3185. Epub 2013 Feb 28.

39.

A metabolically healthy obese phenotype in hispanic participants in the IRAS family study.

Samaropoulos XF, Hairston KG, Anderson A, Haffner SM, Lorenzo C, Montez M, Norris JM, Scherzinger AL, Chen YD, Wagenknecht LE.

Obesity (Silver Spring). 2013 Nov;21(11):2303-9. doi: 10.1002/oby.20326. Epub 2013 May 29.

40.

Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study.

Wong YW, Thomas L, Sun JL, McMurray JJ, Krum H, Hernandez AF, Rutten GE, Leiter LA, Standl E, Haffner SM, Mazzone T, Martinez FA, Tognoni G, Giles T, Califf RM.

Circ Heart Fail. 2013 Mar;6(2):203-10. doi: 10.1161/CIRCHEARTFAILURE.112.000086. Epub 2013 Feb 6.

PMID:
23388113
41.

Assessment of cardiometabolic risk and prevalence of meeting treatment guidelines among patients with type 2 diabetes stratified according to their use of insulin and/or other diabetic medications: results from INSPIRE ME IAA.

Smith J, Nazare JA, Borel AL, Aschner P, Barter PJ, Van Gaal L, Matsuzawa Y, Kadowaki T, Ross R, Brulle-Wohlhueter C, Alméras N, Haffner SM, Balkau B, Després JP.

Diabetes Obes Metab. 2013 Jul;15(7):629-41. doi: 10.1111/dom.12075. Epub 2013 Feb 24.

PMID:
23356633
42.

The association of alanine aminotransferase within the normal and mildly elevated range with lipoproteins and apolipoproteins: the Insulin Resistance Atherosclerosis Study.

Lorenzo C, Hanley AJ, Rewers MJ, Haffner SM.

Diabetologia. 2013 Apr;56(4):746-57. doi: 10.1007/s00125-012-2826-4. Epub 2013 Jan 24.

43.

Insulin clearance and the incidence of type 2 diabetes in Hispanics and African Americans: the IRAS Family Study.

Lee CC, Haffner SM, Wagenknecht LE, Lorenzo C, Norris JM, Bergman RN, Stefanovski D, Anderson AM, Rotter JI, Goodarzi MO, Hanley AJ.

Diabetes Care. 2013 Apr;36(4):901-7. doi: 10.2337/dc12-1316. Epub 2012 Dec 5.

44.

Components of metabolic syndrome and 5-year change in insulin clearance - the Insulin Resistance Atherosclerosis Study.

Lee CC, Lorenzo C, Haffner SM, Wagenknecht LE, Goodarzi MO, Stefanovski D, Norris JM, Rewers MJ, Hanley AJ.

Diabetes Obes Metab. 2013 May;15(5):441-7. doi: 10.1111/dom.12049. Epub 2013 Jan 21.

45.

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial.

Preiss D, Thomas LE, Sun JL, Haffner SM, Holman RR, Standl E, Leiter LA, Mazzone T, Rutten GE, Tognoni G, Martinez FA, Chiang FT, Califf RM, McMurray JJ.

BMJ Open. 2012 Nov 30;2(6). pii: e001925. doi: 10.1136/bmjopen-2012-001925. Print 2012.

46.

Impact of differences in glucose tolerance on the prevalence of a negative insulinogenic index.

Faulenbach MV, Wright LA, Lorenzo C, Utzschneider KM, Goedecke JH, Fujimoto WY, Boyko EJ, McNeely MJ, Leonetti DL, Haffner SM, Kahn SE; American Diabetes Association GENNID Study Group.

J Diabetes Complications. 2013 Mar-Apr;27(2):158-61. doi: 10.1016/j.jdiacomp.2012.09.011. Epub 2012 Nov 7.

47.

Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators.

N Engl J Med. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799. Epub 2012 Nov 3.

48.

Association between ADIPOQ SNPs with plasma adiponectin and glucose homeostasis and adiposity phenotypes in the IRAS Family Study.

An SS, Hanley AJ, Ziegler JT, Brown WM, Haffner SM, Norris JM, Rotter JI, Guo X, Chen YD, Wagenknecht LE, Langefeld CD, Bowden DW, Palmer ND.

Mol Genet Metab. 2012 Dec;107(4):721-8. doi: 10.1016/j.ymgme.2012.10.003. Epub 2012 Oct 13.

49.

The association of inflammatory and fibrinolytic proteins with 5 year change in insulin clearance: the Insulin Resistance Atherosclerosis Study (IRAS).

Lee CC, Lorenzo C, Haffner SM, Wagenknecht LE, Festa A, Goodarzi MO, Stefanovski D, Olson NC, Norris JM, Rewers MJ, Hanley AJ.

Diabetologia. 2013 Jan;56(1):112-20. doi: 10.1007/s00125-012-2741-8. Epub 2012 Oct 10.

50.

Prediabetes and the risk of diabetes.

McMurray JJ, Haffner SM, Califf RM, Holman RR.

Lancet. 2012 Oct 6;380(9849):1225-6; author reply 1226. doi: 10.1016/S0140-6736(12)61706-1. No abstract available.

PMID:
23040850

Supplemental Content

Loading ...
Support Center